Health AI Central
Peer-Reviewed Publication
ESMO Open2025;10(8):105495.August 1, 2025Journal Article

A radiomics-based artificial intelligence model to assess the risk of relapse in localized colon cancer.

C Prieto-de-la-Lastra1, J A Carbonell-Asins2, A Bueno3, A Gómez-Alderete4, M Busto5, A B Alcolado-Jaramillo6, A Jimenez-Pastor7, X Monzonís8, A Cuñat6, C Montagut9, P Moreno-Ruiz7, M Huerta10, D Roda10, F Gimeno-Valiente11, A Estepa-Fernández7, F Bellvís-Bataller7, A Fuster-Matanzo7, J Gibert8, S Roselló10, C Martinez-Ciarpaglini12, J Vidal9, Á Alberich-Bayarri7, A Cervantes13, N Tarazona14
1Quantitative Imaging Biomarkers in Medicine, Quibim S.L., Madrid, Spain; Medical Image Analysis and Biometry Laboratory, Universidad Rey Juan Carlos, Madrid, Spain.
2Biostatistics Unit, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
3Department of Medical Oncology, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain; Quantitative Imaging Biomarkers in Medicine, Quibim S.L., Valencia, Spain.
4Department of Medical Oncology, Hospital del Mar Research Institute, Universitat Pompeu Fabra, Barcelona, Spain.
5Department of Radiology, Hospital del Mar Research Institute-IMIM, Universitat Pompeu Fabra, Barcelona, Spain.
6Department of Radiology, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, Valencia, Spain.
7Quantitative Imaging Biomarkers in Medicine, Quibim S.L., Valencia, Spain.
8Hospital del Mar Research Institute, Barcelona, Spain.
9Department of Medical Oncology, Hospital del Mar Research Institute, Universitat Pompeu Fabra, Barcelona, Spain; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
10Department of Medical Oncology, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
11Department of Medical Oncology, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
12CIBERONC, Instituto de Salud Carlos III, Madrid, Spain; Department of Pathology, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
13Department of Medical Oncology, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain. Electronic address: andres.cervantes@uv.es.
14Department of Medical Oncology, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain. Electronic address: noetalla@incliva.es.
PubMed PMC DOI PDF

Abstract

BACKGROUND: Accurately estimating relapse risk in localized colon cancer (LCC) remains a challenge, as clinicopathological staging often fails to differentiate patients with a higher likelihood of recurrence. There is a need for novel tools to improve patient selection for post-operative chemotherapy. Radiomics has emerged as a powerful, noninvasive approach that may enhance clinical decision maki…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.